新里程健康科技集团股份有限公司第七届董事会第四次会议决议公告

Group 1 - The company held its fourth meeting of the seventh board of directors on February 14, 2026, with all 11 directors present, and the meeting was conducted in accordance with relevant laws and regulations [1][2][4]. - The board approved a proposal for the company to apply for a working capital loan from Gansu Bank Co., Ltd. with a total credit limit of RMB 250 million, which includes a working capital loan of RMB 230 million and an overdraft limit of RMB 20 million [3]. - The loan will be secured by a pledge of the company's 100% equity in Kangxian Duyiwei Biological Pharmaceutical Co., Ltd., with additional guarantees provided by its wholly-owned subsidiaries [3]. Group 2 - The board authorized the management to handle the necessary procedures and sign relevant legal documents within the approved loan limit [3]. - The resolution was passed unanimously with 11 votes in favor, and no votes against or abstentions [4]. - The meeting's resolutions and related documents will be available for review [5].